US-based biopharmaceutical company Nurix Therapeutics has reported positive clinical data from its ongoing Phase Ia/Ib trial of NX-5948, a BTK degrader designed to treat relapsed/refractory Waldenstrom’s macroglobulinaemia (WM).
The findings were shared at the 12th International Workshop on Waldenstrom’s Macroglobulinemia in Prague, Czech Republic, which was held from 17 to 19 October.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
WM is a rare non-Hodgkin’s lymphoma marked by abnormal lymphocytes and monoclonal immunoglobulin M (IgM) production.
As of 17 April, the trial data showed NX-5948’s safety across all dosages from 50mg to 600mg administered orally daily.
In the trial, the therapy showed an objective response in seven out of nine evaluable patients (77.8%), with two patients showing stable disease.
Seven responses were recorded at the first eight-week assessment while five patients are still undergoing treatment, with two of these patients having been treated for more than a year.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataNurix chief medical officer Paula O’Connor said: “We are encouraged by the emerging positive data from NX-5948 in patients with Waldenstrom’s macroglobulinemia, which adds to the previously disclosed robust clinical activity observed in patients with chronic lymphocytic leukaemia.
“These data support our decision to advance NX-5948 into the ongoing Phase 1b expansion cohort in patients who have previously received at least one prior line of therapy including a BTK inhibitor and patients presenting with Bing-Neel syndrome, a rare form of WM with central nervous system involvement where NX-5948’s ability to penetrate the brain may offer a distinct advantage.”
Further data from 10 October included details on the first 13 WM subjects enrolled in both the Phase Ia and Ib stages of the trial.
These patients had a median age of 74 and had undergone an average of three previous therapies, including BTK inhibitors and chemo-immunotherapy.
Based in California, Nurix Therapeutics focuses on developing and commercialising therapies for cancer, inflammatory conditions and other diseases.
